Frontier Specialty Chemicals develops and provides process to produce active pharmaceutical
ingredient for clinical trial of COVID-19 therapeutic investigational drug RBT-9
June 23, 2020 | Press Release
―Renibus Therapeutics Will Conduct Phase 2 Trial of Compound with Antiviral and
Immune-Modulating Activity to treat effects of COVID-19 ―
Logan, UT – June 23, 2020 – Frontier Specialty Chemicals, a world leader in porphyrin chemistry and chemical building blocks for drug discovery and material science research, today announced their collaboration with Renibus Therapeutics to develop a therapeutic for COVID-19. Frontier Specialty Chemicals identified and developed multiple synthetic processes to produce stannous protoporphyrin (SnPP) – the active pharmaceutical ingredient of RBT-9, an investigational drug entering a Phase 2 trial for the treatment of COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease. RBT-9, which has been awarded Fast Track designation by the U.S. Food and Drug Administration (FDA), has demonstrated both antiviral and immune-modulating activities in preclinical studies.
RBT-9 is being developed by Renibus Therapeutics as an antiviral agent with organ-protective attributes. With the advent of the coronavirus pandemic, Renibus scientists moved quickly to plan and initiate a clinical trial of RBT-9 in COVID-19 patients. They chose Frontier Specialty Chemicals to develop a scalable process with robust chemical techniques allowing RBT-9 to be produced under cGMP protocols for use in human clinical trials, said Dustin Cefalo, PhD, VP of Porphyrin Chemistry at Frontier Specialty Chemicals.
Al Guillem, CEO, of Renibus stated, “Renibus Therapeutics Inc., is pleased to be partnering with Frontier Specialty Chemicals on the manufacturing and supply of RBT-9 for study REN-005 “A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Preventing Progression of COVID-19 in High-Risk Individuals.” Frontier Specialty Chemicals’ ability to quickly react and support our clinical study efforts during these critical times is a testament to their commitment to deliver superior service and support to their partners.”
Upon development of the synthetic process for production of SnPP, Frontier Specialty Chemicals transferred their processes and know-how to an outside GMP facility for production of the active pharmaceutical ingredient for Renibus Therapeutics. Frontier Specialty Chemicals continues to provide technical consultation and problem solving expertise to Renibus Therapeutics with regards to production of SnPP and support the continued development of RBT-9 as a promising therapeutic for the treatment of Covid-19.
About Renibus Therapeutics and RBT-9 : Renibus Therapeutics is developing a novel anti-viral therapy, RBT-9 (stannous protoporphyrin–SnPP), for the treatment of COVID-19 in early stage patients who are asymptomatic or mildly symptomatic and at high risk for disease progression. Renibus is investigating the ability of RBT-9 both to inhibit viral activity and to prevent organ failure in COVID-19 patients. For more information visit https://renibus.com/#contact.
About Frontier Specialty Chemicals: Frontier Specialty Chemicals specializes in research and development, custom synthesis, process development, scale-up, and quality manufacturing of specialized compounds and fine chemicals. Our skilled chemists have developed compounds for use in drug discovery, FDA approved medical devices, and in chemical and life sciences research. It has been our philosophy for over 40 years that innovative solutions and accountability to our clients are key components of successful custom research projects. We view quality as a guiding principle, achieved by rigorous scientific diligence at each step of the development and manufacturing process. Frontier Specialty Chemicals is headquartered in Logan, UT.For more information, visit https://frontierspecialtychemicals.com.
Contacts: Frontier Specialty Chemicals, Inc sales@frontierspecialtychemicals.com, 1-435-753-1901
June 23, 2020 | Press Release